The Macrogen-backed gut microbiome drug developer went public in a $22.5m offering priced at the foot of its range.

Microba Life Sciences, an Australia-based microbiome measurement technology developer backed by genetic analysis technology producer Macrogen, floated in a A$30m ($22.5m) initial public offering on the Australian Stock Exchange (ASX) on Monday. The offering involved the sale of 66.7 million shares at the bottom end of its A$0.45 to A$0.50 range, giving the company a…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.